Yuh-Ling Chen Selected Research

1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)

1/2022	Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts.
1/2021	Autophagy Drives Galectin-1 Secretion From Tumor-Associated Macrophages Facilitating Hepatocellular Carcinoma Progression.
12/2019	A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer.
1/2017	Glycosylation-dependent galectin-1/neuropilin-1 interactions promote liver fibrosis through activation of TGF-β- and PDGF-like signals in hepatic stellate cells.
10/2014	Galectin-1 induces vascular permeability through the neuropilin-1/vascular endothelial growth factor receptor-1 complex.
3/2011	Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression.
3/2009	Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuh-Ling Chen Research Topics

Disease

26	Neoplasms (Cancer) 03/2022 - 08/2007
9	Squamous Cell Carcinoma of Head and Neck 10/2014 - 04/2008
8	Neoplasm Metastasis (Metastasis) 03/2022 - 04/2008
6	Mouth Neoplasms (Oral Cancer) 01/2021 - 03/2009
5	Prostatic Neoplasms (Prostate Cancer) 12/2014 - 04/2002
4	Lung Neoplasms (Lung Cancer) 03/2022 - 08/2007
4	Carcinoma (Carcinomatosis) 01/2022 - 03/2011
4	Carcinogenesis 07/2019 - 08/2007
3	Adenocarcinoma of Lung 01/2022 - 03/2009
3	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 05/2010
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 01/2017
2	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 01/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2019 - 01/2013
2	Virus Diseases (Viral Diseases) 01/2015 - 10/2011
1	Fibrosis (Cirrhosis) 01/2022
1	Hyperplasia 01/2021
1	Diabetes Mellitus 01/2015
1	Wounds and Injuries (Trauma) 01/2015
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2014
1	Hypoxia (Hypoxemia) 01/2014
1	Tics (Tic) 03/2013
1	Rheumatoid Arthritis 03/2012
1	Arthritis (Polyarthritis) 03/2012
1	Experimental Arthritis 03/2012
1	Infections 10/2011
1	Human Influenza (Influenza) 10/2011
1	Inflammation (Inflammations) 10/2011
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 08/2011
1	Leukemia 08/2011
1	Glomerulonephritis 10/2010
1	Rheumatic Heart Disease (Rheumatic Heart Diseases) 10/2010

Drug/Important Bio-Agent (IBA)

10	Galectin 1 (LGALS1)IBA 01/2022 - 04/2008
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2007
7	1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA 01/2022 - 03/2009
4	Biomarkers (Surrogate Marker)IBA 03/2022 - 06/2011
4	Peptides (Polypeptides)IBA 12/2014 - 02/2005
4	Small Interfering RNA (siRNA)IBA 01/2013 - 08/2007
3	MicroRNAs (MicroRNA)IBA 01/2020 - 03/2013
3	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 08/2011
3	Neuropilin-1IBA 01/2017 - 08/2007
3	Androgen Receptors (Androgen Receptor)IBA 12/2014 - 04/2002
2	Therapeutic UsesIBA 03/2022 - 07/2019
2	LectinsIBA 01/2022 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 04/2002
2	Galectins (Galectin)IBA 01/2017 - 03/2009
2	PlatinumIBA 09/2016 - 08/2011
2	IntegrinsIBA 05/2014 - 01/2013
2	Pharmaceutical PreparationsIBA 01/2014 - 08/2011
1	Nucleotide AptamersIBA 03/2022
1	Annexin A2 (Annexin II)IBA 03/2022
1	Type I Tumor Necrosis Factor ReceptorsIBA 01/2022
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2022
1	NucleotidesIBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	16S Ribosomal RNAIBA 01/2021
1	Amino Acids FDA Link 01/2021
1	Histone Deacetylase InhibitorsIBA 01/2020
1	AgarIBA 01/2020
1	Vorinostat FDA Link 01/2020
1	trichostatin A (A 300)IBA 01/2020
1	Claudin-1IBA 01/2020
1	Tight Junction ProteinsIBA 01/2020
1	A-Form DNA (A-DNA)IBA 12/2019
1	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2019
1	Sirolimus (Rapamycin)FDA Link 07/2019
1	ErbB Receptors (EGF Receptor)IBA 07/2019
1	Tyrosine Kinase InhibitorsIBA 07/2019
1	AfatinibIBA 07/2019
1	dactolisibIBA 07/2019
1	CXC ChemokinesIBA 10/2018
1	Carrier Proteins (Binding Protein)IBA 01/2017
1	Polysaccharides (Glycans)IBA 01/2017
1	Adenosine Triphosphatases (ATPase)IBA 09/2016
1	EnzymesIBA 09/2016
1	Cardiac GlycosidesIBA 09/2016
1	Indicators and Reagents (Reagents)IBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	Streptozocin (Streptozotocin)FDA Link 01/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2014
1	Tumor Biomarkers (Tumor Markers)IBA 10/2013
1	CateninsIBA 03/2013
1	integrin-linked kinaseIBA 01/2013
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2013
1	CytokinesIBA 03/2012
1	Glycoproteins (Glycoprotein)IBA 10/2011
1	SphingolipidsIBA 08/2011
1	Glycogen Synthase KinasesIBA 08/2011
1	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 08/2011
1	CeramidesIBA 08/2011
1	Galectin 3 (LGALS3)IBA 08/2011
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2011
1	Guanine Nucleotide Dissociation Inhibitors (GDIs)IBA 06/2011
1	Conditioned Culture MediaIBA 03/2011
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 03/2011
1	AntigensIBA 10/2010

Therapy/Procedure

6	Therapeutics 03/2022 - 03/2012
4	Drug Therapy (Chemotherapy) 01/2020 - 08/2011
1	Precision Medicine 03/2022
1	Immunotherapy 12/2019
1	Subcutaneous Injections 01/2015